Replies to post #202956 on Biotech Values

[DewDiligence]

(RVNC)—Ipsen’s reports €73.9M 3Q16 Dysport, +9% YoY in constant currency:

http://finance.yahoo.com/news/ipsen-reports-12-2-1-050000626.html

3Q16 Dysport sales were -3% QoQ due to normal seasonality in the cosmetic portion of the botulinum-toxin market, where the second and fourth calendar quarters are stronger than the first and third.

Dysport is a weak Botox competitor. RVNC's RT-002 is a clearly superior product, IMO.